CAS No. :	100643-71-8
Formula :	C₁₉H₁₉ClN₂
M.W :	310.82
SMILES Code :	ClC1=CC=C2C(CCC3=CC=CN=C3/C2=C4CCNCC/4)=C1
Synonyms :	Sch34117; Descarboethoxyloratadine; Aerius
MDL No. :	MFCD00871949
InChI Key :	JAUOIFJMECXRGI-UHFFFAOYSA-N
Pubchem ID :	124087

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

CHO-K1 cells	3.48 μM		Evaluate the inhibitory effect of DLT on 5HT2AR	Aging Cell. 2021 Jan;20(1):e13286.
HepG2 cells	2-10 μg/ml	48 hours	To evaluate the inhibitory effect of desloratadine on HCC cell proliferation, results showed significant reduction in cell viability	Signal Transduct Target Ther. 2023 Jan 9;8(1):14
Huh7 cells	2-10 μg/ml	48 hours	To evaluate the inhibitory effect of desloratadine on HCC cell proliferation, results showed significant reduction in cell viability	Signal Transduct Target Ther. 2023 Jan 9;8(1):14
Hep3B cells	6 μg/ml		Inhibited cell proliferation	Signal Transduct Target Ther. 2023 Jan 9;8(1):14.
SK-Hep1 cells	6 μg/ml		Inhibited cell proliferation	Signal Transduct Target Ther. 2023 Jan 9;8(1):14.
HepG2 cells	2-10 μg/ml	48 h	Inhibited HCC cell proliferation and induced apoptosis	Signal Transduct Target Ther. 2023 Jan 9;8(1):14.
Huh7 cells	2-10 μg/ml	48 h	Inhibited HCC cell proliferation and induced apoptosis	Signal Transduct Target Ther. 2023 Jan 9;8(1):14.
human small airway epithelial cells (AEC)	16 µM, 32 µM, 64 µM	2 h	Desloratadine reduced the SPRBD-induced increases in CHST15 and CHST11 mRNA expression and partially reversed the SPRBD-induced declines in ARSB activity and expression.	Signal Transduct Target Ther. 2024 Feb 14;9(1):39.
ACE2 overexpressing HEK293T cells	1, 5, 10, 20 μM	48 h	To evaluate the inhibitory effect of Desloratadine on the entry of SARS-CoV-2 pseudotyped virus into cells, results showed that Desloratadine significantly inhibited the viral entry and was more effective than Loratadine	Chem Biol Interact. 2021 Apr 1;338:109420.

APP/PS1 mice	Alzheimer's disease model	Oral	20 mg/kg/day	Once daily for three months	DLT ameliorated pathological behavior of APP/PS1 mice by antagonizing 5HT2AR, including improving short-term working memory defect, spatial working memory defect, and learning performance defect.	Aging Cell. 2021 Jan;20(1):e13286.
APP/PS1 mice	Alzheimer's disease model mice	Oral	20 mg/kg/day	Once daily for three months	Evaluate the ameliorative effect of DLT on pathological behavior of APP/PS1 mice	Aging Cell. 2021 Jan;20(1):e13286.
Nude mice	HCC xenograft model	Oral	15 or 45 mg/kg	Once every two days for 2-3 weeks	To evaluate the inhibitory effect of desloratadine on HCC tumor growth, results showed significant suppression of tumor growth	Signal Transduct Target Ther. 2023 Jan 9;8(1):14
Nude mice	Huh7 and HepG2 cells-derived xenograft models	Oral	15 or 45 mg/kg	Once every two days for 2-3 weeks	Significantly suppressed tumor growth	Signal Transduct Target Ther. 2023 Jan 9;8(1):14.

NCT00884325	-		Completed	-	-
NCT03724240	Hay Fever	Phase 3	Not yet recruiting	December 2019	-
NCT03517930	Clinical Pharmacology	Phase 1	Completed	-	United States, New Jersey ... More >> Frontage Clinical Services Secaucus, New Jersey, United States, 07094 Less <<
NCT00866788	Chronic Idiopathic Urticaria	Phase 2	Completed	-	-
NCT00866788	-		Completed	-	-
NCT00633919	-		Completed	-	-
NCT00310466	Allergy	Phase 3	Completed	-	Germany ... More >> Charité Klinik für Dermatologie, Venerologie und Allergologie Berlin, Germany, D-10117 Less <<
NCT00633919	Allergy	Phase 2 Phase 3	Completed	-	Spain ... More >> Fernando Rodríguez Santander, Cantabria, Spain Less <<
NCT00310466	-		Completed	-	-
NCT01940393	Urticaria	Phase 4	Completed	-	Colombia ... More >> Medellin Medellin, Antioquia, Colombia Less <<
NCT02593747	Histamine H1 Antagonists, Non-... More >>Sedating Less <<	Phase 1	Completed	-	Germany ... More >> Neu-Ulm, Bayern, Germany, 89231 Less <<
NCT00884325	Atopic Dermatitis ... More >> Pruritus Less <<	Phase 4	Completed	-	United States, Kentucky ... More >> DermResearch, PLLC Louisville, Kentucky, United States, 40217 Less <<
NCT00730912	-		Completed	-	-
NCT03517943	Clinical Pharmacology	Phase 1	Completed	-	United States, New Jersey ... More >> Frontage Clinical Services Secaucus, New Jersey, United States, 07094 Less <<
NCT01740284	Allergic Rhinoconjunctivitis	Phase 3	Completed	-	Germany ... More >> Zentrum für Rhinologie und Allergologie Wiesbaden, Germany, 65183 Less <<
NCT00730912	Perennial Allergic Rhinitis	Phase 4	Completed	-	-
NCT00160537	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT01985789	Asthma	Phase 4	Completed	-	Canada, Saskatchewan ... More >> University of Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 0W8 Less <<
NCT00521170	Allergy	Phase 1	Completed	-	France ... More >> Illkirch, France Strasbourg, France Less <<
NCT00160589	Rhinitis, Allergic, Perennial	Phase 4	Completed	-	-
NCT03751111	Chronic Pruritus	Phase 1 Phase 2	Not yet recruiting	February 1, 2019	-
NCT00967967	Asthma Rhinit... More >>is Less <<	Not Applicable	Suspended(Awaiting results fro... More >>m sub analysis to decide if study continuesé) Less <<	September 2014	Canada, Quebec ... More >> Institut universitaire de cardiologie et de pneumologie de Québec Québec, Quebec, Canada, G1V 4G5 Less <<
NCT01400828	Seasonal Allergic Rhinitis	Phase 3	Completed	-	Korea, Republic of ... More >> Yonsei University college of Medicine, Gangnam Severance Hospital Seoul, Korea, Republic of Less <<
NCT02507635	Allergic Rhinitis	Phase 4	Completed	-	-
NCT00264303	Chronic Idiopathic Urticaria	Phase 4	Completed	-	-
NCT00346606	Chronic Idiopathic Urticaria ... More >> Urticaria Less <<	Phase 4	Unknown	-	Taiwan ... More >> Department of Dermatology National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Jia-Yu Chu +886-2-23123456 ext 5734 Principal Investigator: Jia-Yu Chu Less <<
NCT00636870	Allergic Rhinitis	Phase 4	Completed	-	United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00637585	Allergic Rhinitis	Phase 4	Completed	-	United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT01529229	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00424580	Asthma	Not Applicable	Completed	-	Canada, Saskatchewan ... More >> Room 346 Ellis Hall Saskatoon, Saskatchewan, Canada, S7N 0W8 Less <<
NCT01720485	Allergic Rhinitis	Phase 3	Unknown	March 2014	Brazil ... More >> IMA - Instituto de Pesquisa Clínica e Medicina Avançada Not yet recruiting São Paulo, Brazil Contact: Fabio M Castro, MD 55 11 38639156 daniela.fakih@imabrasil.com Principal Investigator: Fabio M Castro, MD Less <<
NCT00264303	-		Completed	-	-
NCT01108783	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00751218	Urticaria	Phase 4	Completed	-	-
NCT00723736	Rhinitis\|Urticaria		COMPLETED	2025-06-08	-
NCT00862225	Seasonal Allergic Rhinitis	Phase 2	Completed	-	Germany ... More >> Dept. of Otorhinolaryngology and Head and Neck Surgery Dusseldorf, Germany Less <<
NCT00723736	Rhinitis\|Urticaria		COMPLETED	2025-06-08	-
NCT00311844	Conjunctivitis, Allergic	Phase 4	Completed	-	-
NCT01916967	Urticaria	Phase 3	Completed	-	-
NCT00751166	Urticaria	Phase 4	Terminated(Study could not be ... More >>re-supplied with study medication in a timely manner.) Less <<	-	-
NCT01916967	-		Completed	-	-
NCT00816972	Post-nasal Drip ... More >> Seasonal Allergic Rhinitis Rhinorrhea Less <<	Phase 2	Completed	-	-
NCT01529242	Cutaneous Hypersensitivity	Phase 3	Terminated(By sponsor decision... More >> due to difficulty of recruitment) Less <<	-	Brazil ... More >> Alergoalpha São Paulo, SP, Brazil Allergisa Campinas, São Paulo, Brazil Hospital Nipo Brasileiro São Paulo, Brazil Less <<
NCT00600847	Acquired Cold Urticaria	Phase 4	Completed	-	Germany ... More >> Allergie-Centrum-Charité Berlin Berlin, Germany, 10117 Less <<
NCT00359138	Hypersensitivity	Phase 4	Completed	-	-
NCT01918033	-		Completed	-	-
NCT00359138	-		Completed	-	-
NCT02320396	Seasonal Allergic Rhinitis	Phase 3	Completed	-	-
NCT00783211	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT01918033	Perennial Allergic Rhinitis	Phase 3	Completed	-	-
NCT00795522	Urticaria	PHASE4	COMPLETED	2025-03-05	-
NCT00783133	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00794248	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00794768	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00783354	Urticaria Chr... More >>onic Idiopathic Urticaria Less <<	Phase 4	Completed	-	-
NCT00794495	Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less <<	Phase 4	Completed	-	-
NCT00794599	Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less <<	Phase 4	Completed	-	-
NCT02320396	-		Completed	-	-
NCT01444196	Urticaria	PHASE4	COMPLETED	2025-05-10	Department of Dermatology, Ven... More >>erology and Allergology, Berlin, 10117, Germany Less <<
NCT00598611	Chronic Urticaria	Phase 3	Completed	-	Germany ... More >> Allergie-Centrum-Charite Berlin, Germany, 10117 Less <<
NCT01916980	Eczema Dermat... More >>itis Dermal Pruritus Less <<	Phase 3	Completed	-	-
NCT00783146	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00406783	Rhinitis, Allergic, Seasonal ... More >> Rhinitis, Allergic, Perennial Less <<	Phase 3	Completed	-	-
NCT00406783	-		Completed	-	-
NCT00794846	Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less <<	Phase 4	Completed	-	-
NCT00704769	-		Completed	-	-
NCT00405964	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00405964	-		Completed	-	-
NCT00805584	Rhinitis, Allergic, Seasonal	Phase 4	Completed	-	-
NCT00780403	Allergies	Phase 4	Completed	-	-
NCT00795158	Urticaria	Phase 3	Completed	-	-
NCT00779636	Allergic Airway Disease	Phase 4	Completed	-	-
NCT01916980	-		Completed	-	-
NCT02904304	Cold	Phase 3	Not yet recruiting	November 2019	Brazil ... More >> Allergisa Pesquisa Dermato Cosmética Ltda. Not yet recruiting Campinas, São Paulo, Brazil Contact: Mauro Crippa Jr. *55 19 3789-8615 Less <<
NCT00794378	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00794794	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00724698	Rhinitis\|Urticaria		COMPLETED	2025-12-07	-
NCT00724698	Rhinitis\|Urticaria		COMPLETED	2025-12-07	-
NCT00780403	-		Completed	-	-
NCT00779116	-		Completed	-	-
NCT00704769	-		Completed	-	-
NCT00779116	Allergies	Phase 4	Completed	-	-
NCT00757562	Chronic Idiopathic Urticaria ... More >> Atopy Less <<	Phase 3	Completed	-	-
NCT00867191	Seasonal Allergic Rhinitis	Phase 4	Completed	-	-
NCT00536380	Chronic Idiopathic Urticaria	Phase 4	Completed	-	-
NCT00761527	-		Completed	-	-
NCT00805324	Rhinitis, Allergic, Seasonal\|A... More >>sthma Less <<	PHASE3	COMPLETED	2025-08-03	-
NCT00789152	Allergic Rhinitis	Phase 3	Completed	-	-
NCT00761527	-		Completed	-	-
NCT01506791	Healthy	Phase 1	Completed	-	United States, Florida ... More >> SFBC Ft Myers Inc Broadway, Florida, United States, 33901 Less <<
NCT01373138	Healthy	Phase 1	Completed	-	Canada ... More >> SFBC Anapharm Sainte-Foy (Quebec), Canada, G1V 2K8 Less <<
NCT02646020	Non-small Cell Lung Cancer	Phase 2	Unknown	December 2017	China, Guangdong ... More >> Cancer Center of Sun-Yat Sen University (CCSYSU) GuangZhou, Guangdong, China, 510060 Less <<
NCT01314339	Fasting	PHASE1	COMPLETED	2025-02-06	SFBC, Ft. Myers, Inc.,, Ft. My... More >>ers, Florida, 33901, United States Less <<
NCT00536380	-		Completed	-	-
NCT01506037	Healthy	PHASE1	COMPLETED	2025-02-06	SFBC Ft Myers Inc, Broadway, F... More >>lorida, 33901, United States Less <<
NCT01314352	Fed	PHASE1	COMPLETED	2025-03-06	SFBC, Ft. Myers, Inc.,, Ft. My... More >>ers, Florida, 33901, United States Less <<
NCT01506050	Healthy	PHASE1	COMPLETED	2025-02-06	SFBC Ft Myers Inc, Broadway, F... More >>lorida, 33901, United States Less <<
NCT00817076	Dermatitis, Atopic	Phase 3	Completed	-	-

{[proInfo.proName]}

CAS No.: 100643-71-8

{[proInfo.proName]}

CAS No.: 100643-71-8

Alternative Products

Product Details of Desloratadine

Safety of Desloratadine

Related Pathways of Desloratadine

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.22mL 0.64mL 0.32mL	16.09mL 3.22mL 1.61mL	32.17mL 6.43mL 3.22mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed